Details for Patent: 7,261,880

Title:	Methods of treating Syndrome X with aliphatic polyamines
Abstract:	The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: ##STR00001## where n is a positive integer and each R, independently, is H or a C.sub.1 C.sub.8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.
Inventor(s):	Burke; Steven K. (Sudbury, MA), Donovan; Joanne M. (Needham, MA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Filing Date:	Apr 17, 2002
Application Number:	10/125,701
Claims:	1. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof, alone or in combination with an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin; an LDL (low density lipoprotein) receptor inducer; a fibrate; vitamin B.sub.6 (also known as pyridoxine) or a pharmaceutically acceptable salt thereof; vitamin B.sub.12; an anti-oxidant vitamin; an angiotensin II antagonist converting enzyeme inhibitor; or a platelet aggregation inhibitor. 2. A method for treating Syndrome X in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable salt thereof.